Haemonetics Corporation
118.51USD
+2.3500 (+2.02%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HAE.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.29▲ | $1.27 | 1 | 0 |
| Next quarter | $1.36▼ | $1.39 | 2 | 0 |
| Current year | $5.31▲ | $5.22 | 2 | 0 |
| Next year | $5.78▲ | $5.63 | 2 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.08 | $1.14 | +0.06 (+5.8%) |
| 2026-03-31 | $1.27 | $1.29 | +0.02 (+1.4%) |
| 2025-12-31 | $1.25 | $1.31 | +0.06 (+4.8%) |
| 2025-09-30 | $1.11 | $1.27 | +0.16 (+14.3%) |
186 ratings from 21 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barrington Research | Maintained | Outperform | $118 $140 | Oct 9, 2026 |
| Mizuho | Maintained | Outperform | $95 $140 | Oct 9, 2026 |
| BTIG | Maintained | Buy | $110 $130 | Oct 8, 2026 |
| Citigroup | Upgraded from Neutral | Buy | $92 $123 | Sep 17, 2026 |
| Raymond James | Maintained | Outperform | $105 $125 | Sep 3, 2026 |
| Baird | Maintained | Outperform | $96 $119 | Aug 21, 2026 |
| Barrington Research | Maintained | Outperform | $95 $118 | Aug 19, 2026 |
| BTIG | Maintained | Buy | $96 $110 | Aug 18, 2026 |
| Citigroup | Maintained | Neutral | $79 $92 | Aug 7, 2026 |
| JP Morgan | Maintained | Neutral | $62 $86 | Aug 7, 2026 |
| BTIG | Maintained | Buy | $84 $96 | Aug 6, 2026 |
| Mizuho | Maintained | Outperform | $85 $90 | Jul 15, 2026 |
| BTIG | Reiterated | Buy | $84 | Jun 26, 2026 |
| BTIG | Reiterated | Buy | $84 | Jun 17, 2026 |
| Mizuho | Maintained | Outperform | $70 $85 | Jun 15, 2026 |
| Citigroup | Maintained | Neutral | $64 $70 | May 28, 2026 |
| B of A Securities | Upgraded from Neutral | Buy | $72 $80 | May 22, 2026 |
| Barrington Research | Maintained | Outperform | $94 $89 | May 12, 2026 |
| JP Morgan | Maintained | Neutral | $74 $62 | May 8, 2026 |
| Mizuho | Maintained | Outperform | $80 $70 | Apr 13, 2026 |
| Citigroup | Maintained | Neutral | $70 $64 | Apr 7, 2026 |
| Citigroup | Maintained | Neutral | $75 $70 | Mar 11, 2026 |
| Citigroup | Maintained | Neutral | $88 $75 | Feb 6, 2026 |
| Mizuho | Maintained | Outperform | $90 $80 | Feb 6, 2026 |
| Barrington Research | Maintained | Outperform | $93 $94 | Feb 6, 2026 |
37 filings from 15 insiders · 0 buy / 0 sell over 6m
Officers and directors of HAE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KROLL MARK WDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| ABERNATHY ROBERT EDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| COYLE MICHAEL JDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| ZANE ELLEN MDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| MADAUS MARTIN D PH.D.Director | Grant | 2.5k | — | — | Jul 24, 2026 |
| POMEROY CLAIREDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| BRYANT DIANE MDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| JOHNSON LLOYD EMERSONDirector | Grant | 2.5k | — | — | Jul 24, 2026 |
| DARECCA JAMESChief Financial Officer | Grant | 29.3k | — | — | May 15, 2026 |
| MILLER LAURIE AOfficer | Grant | 13.3k | — | — | May 15, 2026 |
| GALVIN ROYOfficer | Grant | 27.5k | — | — | May 15, 2026 |
| MAUNSELL FARRIS MARYANNEOfficer | Grant | 2.2k | — | — | May 15, 2026 |
| SIMON CHRISTOPHERChief Executive Officer | Grant | 78.3k | — | — | May 15, 2026 |
| BASIL MICHELLE LGeneral Counsel | Grant | 28.4k | — | — | May 15, 2026 |
| KROLL MARK WDirector | Buy | 1.4k | $70.56 | $99k | Nov 10, 2025 |
| KROLL MARK WDirector | Grant | 2.7k | — | — | Jul 24, 2025 |
| ABERNATHY ROBERT EDirector | Grant | 2.7k | — | — | Jul 24, 2025 |
| COYLE MICHAEL JDirector | Grant | 2.7k | — | — | Jul 24, 2025 |
| ZANE ELLEN MDirector | Grant | 2.7k | — | — | Jul 24, 2025 |
| DOCKENDORFF CHARLES JDirector | Grant | 2.7k | — | — | Jul 24, 2025 |
No analyst notes on HAE yet.
Analyst Ratings
10 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 5 | 2 | 0 | 0 | Buy1.82 |
| 1 mo ago | 4 | 5 | 2 | 0 | 0 | Buy1.82 |
| 2 mo ago | 4 | 4 | 3 | 0 | 0 | Buy1.91 |
| 3 mo ago | 4 | 4 | 3 | 0 | 0 | Buy1.91 |
Members whose judged calls on HAE have played out most reliably.
No settled calls on HAE yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice